Heli Valtanen
University of Helsinki
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Heli Valtanen.
Nature Biotechnology | 1999
Erkki Koivunen; Wadih Arap; Heli Valtanen; Aija Rainisalo; Oula Penate Medina; Pia Heikkilä; Carmela Kantor; Carl G. Gahmberg; Tuula Salo; Yrjö T. Konttinen; Timo Sorsa; Erkki Ruoslahti; Renata Pasqualini
Several lines of evidence suggest that tumor growth, angiogenesis, and metastasis are dependent on matrix metalloproteinase (MMP) activity. However, the lack of inhibitors specific for the type IV collagenase/gelatinase family of MMPs has thus far prevented the selective targeting of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) for therapeutic intervention in cancer. Here, we describe the isolation of specific gelatinase inhibitors from phage display peptide libraries. We show that cyclic peptides containing the sequence HWGF are potent and selective inhibitors of MMP-2 and MMP-9 but not of several other MMP family members. Our prototype synthetic peptide, CTTHWGFTLC, inhibits the migration of human endothelial cells and tumor cells. Moreover, it prevents tumor growth and invasion in animal models and improves survival of mice bearing human tumors. Finally, we show that CTTHWGFTLC–displaying phage specifically target angiogenic blood vessels in vivo. Selective gelatinase inhibitors may prove useful in tumor targeting and anticancer therapies.
Nature Medicine | 2002
Wadih Arap; Mikhail G. Kolonin; Martin Trepel; Johanna Lahdenranta; Marina Cardó-Vila; Ricardo J. Giordano; Paul J. Mintz; Peter Ardelt; Virginia J. Yao; Claudia I. Vidal; Limor Chen; Anne L. Flamm; Heli Valtanen; Lisa Weavind; Marshall E. Hicks; Raphael E. Pollock; Gregory H. Botz; Corazon D. Bucana; Erkki Koivunen; Dolores J. Cahill; Patricia Troncoso; Keith A. Baggerly; Rebecca D. Pentz; Kim Anh Do; Christopher J. Logothetis; Renata Pasqualini
The molecular diversity of receptors in human blood vessels remains largely unexplored. We developed a selection method in which peptides that home to specific vascular beds are identified after administration of a peptide library. Here we report the first in vivo screening of a peptide library in a patient. We surveyed 47,160 motifs that localized to different organs. This large-scale screening indicates that the tissue distribution of circulating peptides is nonrandom. High-throughput analysis of the motifs revealed similarities to ligands for differentially expressed cell-surface proteins, and a candidate ligand–receptor pair was validated. These data represent a step toward the construction of a molecular map of human vasculature and may have broad implications for the development of targeted therapies.
Journal of drug delivery | 2011
Oula Penate Medina; Merja Haikola; Marja Tähtinen; Ilkka Simpura; Sami Kaukinen; Heli Valtanen; Ying Zhu; Sari Kuosmanen; Wei Cao; Justus Reunanen; Tuula Nurminen; Per E. J. Saris; Peter Smith-Jones; Michelle S. Bradbury; Steven M. Larson; Kalevi Kairemo
Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.
Combinatorial Chemistry & High Throughput Screening | 2003
Mikael Björklund; Heli Valtanen; Harri Savilahti; Erkki Koivunen
Screening of phage display libraries allows rapid identification of peptides binding to a target. However, functional analysis of the phage sequences and their reproduction as soluble and stable peptides are often the most time-consuming part in the screening. We have used here intein-based peptide biosynthesis to produce a phage-display derived gelatinase inhibitory peptide CTTHWGFTLC and to identify the critical residues for gelatinase inhibitory activity by performing alanine-scanning mutagenesis. By biosynthetic incorporation of 5-fluorotryptophan, we obtained an inhibitor of MMP-2 and MMP-9 gelatinases that showed a 6-fold enhancement in serum stability in comparison to the wild-type peptide. The new peptide also had an improved ability to inhibit tumor cell migration. These studies indicate the utility of intein methodology for synthesis and design of peptides obtained by phage display.
Biochemical Journal | 1998
Kaisa Lehti; Jouko Lohi; Heli Valtanen; Jorma Keski-Oja
Journal of Biological Chemistry | 2000
Kaisa Lehti; Heli Valtanen; Sara A. Wickström; Jouko Lohi; Jorma Keski-Oja
Gene | 2000
Jouko Lohi; Kaisa Lehti; Heli Valtanen; William C. Parks; Jorma Keski-Oja
Anticancer Research | 2005
Oula Penate Medina; Kalevi Kairemo; Heli Valtanen; Aino Kangasniemi; Sami Kaukinen; Ilona Ahonen; Perttu Permi; Arto Annila; Mia Sneck; Juha M. Holopainen; Sirkka-Liisa Karonen; Paavo K. J. Kinnunen; Erkki Koivunen
Archive | 2004
Ying Zhu; Heli Valtanen; Sami Kaukinen; Medina Oula Penate; Ilkka Simpura
Protein Expression and Purification | 2000
Heli Valtanen; Kaisa Lehti; Jouko Lohi; Jorma Keski-Oja